Abstract: The present invention relates generally to a sensor for tumor tissue and a local release system for releasing therapeutic agents/diagnostic agents for targeted tumor therapy and diagnosis. More specifically, the invention relates to a cation-stabilised biopolymer gel, in particular an alginate gel, for use as a carrier matrix for a tumor therapeutic agent and/or tumor diagnostic agent, characterised in that the gel destabilises in the presence of a stimulus, in particular lysyl oxidase (LOX), generated by tumor cells or tumor tissue and the tumor therapeutic agent and/or tumor diagnostic agent can be released, and a pharmaceutical composition that comprises this cation-stabilised biopolymer gel with incorporated tumor therapeutic agent and/or tumor diagnostic agent and optionally an additional reporter substance.

Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanoparticles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration. The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.

Abstract: The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity.

Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for clinical use in photodynamic therapy comprising a hydrophobic photosensitizer, poly(lactic-co-glycolic) acid and stabilizing agents are provided. These nanoparticulate pharmaceutical formulations provide therapeutically effective amounts of photosensitizer for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers, whose efficacy and safety are enhanced by such nanoparticulate formulations. It also teaches the method of preparing PLGA-based nanoparticles under sterile conditions. In one of the preferred embodiments of the present invention PLGA-based nanoparticles have a mean particle size less than 500 nm and the photosensitizer is temoporfin, 5,10,15,20-tetrakis(3-hydroxyphenyl)-chlorin (mTHPC).

Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanoparticles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration. The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.